Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepoCyte for CNS Relapse in Leukemia and Lymphoma
NCT00388531Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Mar 2006
- Primary completion
- Mar 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal cytarabine in acute lymphoblastic leukemia (ALL) and Burkitt lymphoma (BL), sponsored by Fundación PETHEMA. Primary endpoint: Response Rate after one application of DepoCyte at 1 year. Started Mar 2006; status: completed.
02
Drugs
liposomal cytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT00388531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388531.